Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 15 2024 - 4:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced the appointment of Dallas
Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s
health business unit, effective immediately.
Dr. Reed brings nearly 15 years of clinical and academic
experience rooted in genetics and obstetrics/gynecology to Myriad.
In her new role, she will support internal and external efforts to
increase access to, and equity around, genetic testing throughout a
woman’s health journey including family planning, pregnancy
management and hereditary cancer risk assessment.
“We’re thrilled to welcome Dallas to the Myriad team. She is a
passionate women’s health leader and patient advocate who is
committed to advancing diversity, equity and inclusion in clinical
care and education,” said Melissa Gonzales, president of women’s
health, Myriad Genetics. “She will be instrumental in helping us
further our mission to advance the health and well-being for all
patients.”
Dr. Reed is an OBGYN and Medical Geneticist who serves as the
Chief of Genetics at Tufts Medical Center and as an Associate
Professor at Tufts University School of Medicine. She is board
certified in obstetrics/gynecology and medical genetics. She also
serves as a board member for the Boston Market of the March of
Dimes. She holds a Doctor of Medicine degree from Boston University
School of Medicine and a B.S. in biology from Dillard
University.
"I truly believe in the importance of bringing a real-world
perspective to the critical work being done in the genetic testing
space for hereditary cancer risk and reproductive health,” said Dr.
Reed. “There are many exciting developments ahead that will make it
easier for OBGYNs to provide equitable care and increase patients’
knowledge about their genetics. I look forward to the opportunity
to lend my experience to help clinicians in our field.”
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including that
Dr. Reed will be instrumental in helping the company further its
mission to advance the health and well-being for all patients.
These “forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on March 1, 2023, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
To view Dr. Dallas Reed: Myriad Genetics, Inc.
today announced the appointment of Dallas Reed, MD, FACOG, FACMG as
Principal Medical Advisor to its women’s health business unit,
effective immediately, please visit the following
link: https://www.globenewswire.com/NewsRoom/AttachmentNg/2d25de3e-04c2-4694-b218-f3a6ab4d2486
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024